Data from Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
Aslı D. Munzur, Cameron Herberts, Edmond M. Kwan, Louise Emmett et autres
1 citation
James P Buteau
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
66Publications signalées
1959Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsCancer Genomics and Diagnostics
Publications récentes
Supplementary Figures S1 - S10 from Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
Aslı D. Munzur, Cameron Herberts, Edmond M. Kwan, Louise Emmett et autres
0 citations
Supplementary Tables S1 - S6 from Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
Aslı D. Munzur, Cameron Herberts, Edmond M. Kwan, Louise Emmett et autres
0 citations
Fully automated deep learning-based algorithm for contouring primary malignancy on PSMA PET/CT: results from the proPSMA trial in men with intermediate to high-risk prostate cancer
Ramin Alipour, Binyan Hu, Price Jackson, James P Buteau et autres
0 citationsThe EANM Journal
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
Shahneen Sandhu, A. M. Joshua, Louise Emmett, Mathias Bressel et autres
4 citationsThe Lancet Oncology
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
Aslı D. Munzur, Cameron Herberts, Edmond M. Kwan, Louise Emmett et autres
5 citationsClinical Cancer Research
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617
Heidi Fettke, Louise Kostos, Maria Docanto, Patricia Bukczynska et autres
6 citationsEuropean Urology
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
Louise Kostos, James P Buteau, Jing Xie, Anthony Cardin et autres
16 citationsThe Lancet Oncology
Prognostic Value of Initial Imaging and PSA Change with [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
David C Chen, James P Buteau, Nathan Papa, Tim Akhurst et autres
5 citationsJournal of Nuclear Medicine
Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [ 68 Ga]PSMA-11 or [ 18 F]DCFPyL, [ 18 F]FDG, and [ 177 Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network
Price Jackson, James P Buteau, Lachlan McIntosh, Y. Sun et autres
8 citationsJournal of Nuclear Medicine
Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials
Raghava Kashyap, James P Buteau, Mathias Bressel, Michal Eifer et autres
18 citationsJournal of Nuclear Medicine
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
James P Buteau, Louise Kostos, Price Jackson, Jing Xie et autres
53 citationsThe Lancet Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.